Complete Bibliography
Visit PubMed to view Dr. Larry Corey's full publication record.
Select Recent Publications (selected from over 850)
2025
Corey L, Ratevosian J, Beyrer C, Currier J, Eron J, Cohen MS, Deeks SG. How HIV research drives health innovation in multiple diseases. Nat Med. 2025 Oct 24.
Ellison ST, Hayman I, Derr K, Derr P, Frebert S, Itkin Z, Shen M, Jones A, Olson W, Corey L, Wald A, Johnston C, Fong Y, Ferrer M, Zhu J. Limitations of acyclovir and identification of potent HSV antivirals using 3D bioprinted human skin equivalents. Nat Commun. 2025 Oct 16;16(1):9200.
Laing KJ, Sholukh AM, MacPhee KJ, McClurkan CL, Pagnon A, Ruiz J, Bchir S, Oualim A, Hyrien O, Corey L, Wald A, Gurunathan S, Noriega F, Coronel D, Koelle DM. Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infection. Vaccine. Volume 65, 24 October 2025, 127821.
Weinstein E, Paredes R, Gardner A, Almas M, Baniecki ML, Guan S, Tudone E, Antonucci S, Gregg K, Garcia-Vidal C, Camacho-Ortiz A, Wisemandle W, Terra SG, Liu S, Aberg JA, Rana MM, Corey L, Ford ES, Hammond J, Rusnak J. Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00221-X.
2024
Beyrer C, Tomaras GD, Gelderblom HC, Gray GE, Janes HE, Bekker LG, Millett G, Pantaleo G, Buchbinder S, Corey L. Is HIV epidemic control by 2030 realistic? Lancet HIV. 2024 Jul;11(7):e489-e494.
Ford ES, Li AZ, Laing KJ, Dong L, Diem K, Jing L, Mayer-Blackwell K, Basu K, Ott M, Tartaglia J, Gurunathan S, Reid JL, Ecsedi M, Chapuis AG, Huang ML, Magaret AS, Johnston C, Zhu J, Koelle DM, Corey L. Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine. JCI Insight 2024 Jun 18;9(14):e179010.
Eichholz K, Fukazawa Y, Peterson CW, Haeseleer F, Medina M, Hoffmeister S, Duell DM, Varco-Merth BD, Dross S, Park H, Labriola CS, Axthelm MK, Murnane RD, Smedley JV, Jin L, Gong J, Rust BJ, Fuller DH, Kiem HP, Picker LJ, Okoye AA, Corey L. Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers. J Clin Invest. 2024 Apr 1;134(7):e169309.
Juraska M, Bai H, deCamp AC, Magaret CA, Li L, Gillespie K, Carpp LN, Giorgi EE, Ludwig J, Molitor C, Hudson A, Williamson BD, Espy N, Simpkins B, Rudnicki E, Shao D, Rossenkhan R, Edlefsen PT, Westfall DH, Deng W, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, Yssel A, Matten D, York T, Beaume N, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Karuna ST, Morris L, Montefiori DC, Hural JA, Cohen MS, Corey L, Rolland M, Gilbert PB, Williamson C, Mullins JI. Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2308942121.
2023
St Germain R, Bossard EL, Corey L, Sholukh AM. Serum concentration of antigen-specific IgG can substantially bias interpretation of antibody-dependent phagocytosis assay readout. iScience. 2023 Aug 3;26(9):107527.
Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG; COVID-19 Prevention Network. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023 Jan 3;6(1):e2251974.
2022
Corey D, Haesseler F, Hou J, and Corey L. Chimeric engulfment receptors: novel engineered receptors that trigger T-cell effector functions against SIV infected CD4+ T cells. Mol Ther Methods Clin Dev. 2022 Nov 15;28:1-10.
Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, Ghiuzeli CM, Barnhill S, Sack CL, Benditt JO, Roychoudhury P, Greninger AL, Shapiro AE, Hammond JL, Rusnak JM, Dolsten M, Boeckh M, Liu C, Cheng GS, Corey L. Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir. Clin Infect Dis. 2022 Nov 3:ciac868.
A blog series discussing the evolving science and policy of COVID-19 vaccines, led by internationally renowned experts in vaccine development, Dr. Larry Corey of the Univeristy of Washington/Fred Hutch, and Dr. Chris Beyrer of Johns Hopkins University.
2021
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416.
2020
Haeseleer F, Eichholz K, Tareen SU, Iwamoto N, Roederer M, Kirchhoff F, Park H, Okoye AA, Corey L. Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell. AIDS Res Hum Retroviruses. 2020 Dec;36(12):998-1009.
McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O'Connor T, Sholukh AM, Bossard EL, Phasouk K, Ford ES, Diem K, Klock AM, Jerome KR, Corey L. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. medRxiv. 2020 Jul 21:2020.07.19.20157198.
Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. 2020 May 29;368(6494):948-950.
Randhawa AK, Fisher LH, Greninger AL, Li SS, Andriesen J, Corey L, Jerome KR. Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020. JAMA. 2020 Jun 9;323(22):2334-2336.
Hosseinipour MC, Innes C, Naidoo S, Mann P, Hutter J, Ramjee G, Sebe M, Maganga L, Herce ME, deCamp AC, Marshall K, Dintwe O, Andersen-Nissen E, Tomaras GD, Mkhize N, Morris L, Jensen R, Miner MD, Pantaleo G, Ding S, Van Der Meeren O, Barnett SW, McElrath MJ, Corey L, Kublin JG. Phase 1 HIV vaccine trial to evaluate the safety and immunogenicity of HIV subtype C DNA and MF59-adjuvanted subtype C Env protein. Clin Infect Dis. 2020 Jan 4. pii: ciz1239.
2019
Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 Sep 18;11(510).
Li AZ, Corey L, Zhu J. Random-Reaction-Seed Method for Automated Identification of Neurite Elongation and Branching. Sci Rep. 2019 Feb 27;9(1):2908.
Lo M, Zhu J, Hansen SG, Carroll T, Farr Zuend C, Nöel-Romas L, Ma ZM, Fritts L, Huang ML, Sun S, Huang Y, Koelle DM, Picker LJ, Burgener A, Corey L, Miller CJ. Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. J Virol. 2019 Jan 4;93(2).
2018
Ford ES, Magaret AS, Spak CW, Selke S, Kuntz S, Corey L, Wald A. Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. AIDS. 2018 Nov 13;32(17):2525-2531.
Agyemang E, Magaret AS, Selke S, Johnston C, Corey L, Wald A. Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. J Infect Dis. 2018 Oct 20;218(11):1691-1699.
2017
Peng T, Chanthaphavong RS, Sun S, Trigilio JA, Phasouk K, Jin L, Layton ED, Li AZ, Correnti CE, De van der Schueren W, Vazquez J, O'Day DR, Glass IA, Knipe DM, Wald A, Corey L, Zhu J. Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. J Exp Med. 2017 Aug 7;214(8):2315-2329.
Corey L, Gray GE. Preventing acquisition of HIV is the only path to an AIDS-free generation. Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3798-3800.
Posavad CM, Zhao L, Dong L, Jin L, Stevens CE, Magaret AS, Johnston C, Wald A, Zhu J, Corey L, Koelle DM. Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. Mucosal Immunol. 2017 Sep;10(5):1259-1269.
2016
Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H. Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial. JAMA. 2016 Dec 20;316(23):2495-2503.
Milman N, Zhu J, Johnston C, Cheng A, Magaret A, Koelle DM, Huang ML, Jin L, Klock A, Layton ED, Corey L. In situ detection of regulatory T cells in human genital HSV-2 reactivation and their influence on spontaneous HSV-2 reactivation. J Infect Dis. 2016 Jul 1;214(1):23-31.
2015
Corey L, Gilbert P, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. Immune Correlates of Vaccine Protection Against HIV-1 Acquisition: A Review. Sci Transl Med. 2015 Oct 21;7(310):310rv7.
Reprint | Full Text
Christine M. Posavad, Lin Zhao, Dawn E. Mueller, Claire E. Stevens, Meei Li Huang, Anna Wald and Lawrence Corey. Persistence of mucosal T cell responses to herpes simplex virus type 2 (HSV-2) in the female genital tract. Mucosal Immun. 2015 Jan;8(1):115-26. PMC4263695
Earlier work (2009-2014)
Johnston C, Zhu J, Jing L, Laing K, McClurkan C, Klock A, Diem K, Stanaway J, Tronstein E, Kwok WW, Huang ML, Selke S, Fong Y, Magaret A, Koelle DM, Wald A, and Corey L. Virologic and immunologic evidence of multifocal genital herpes simplex virus type 2 infection. J Virol. 2014 May;88(9):4921-31.
Schiffer JT and Corey L. Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med. 2013 Mar 6;19(3):280-8. NIHMSID559213
Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Obemichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L. Rapid Localized Spread and Immunologic Containment of Herpes Simplex Virus-2 in the Human Genital Tract. eLife. 2013;2:e00288.
Zhu J, Peng T, Johnston C, Phasouk K, Kask AS, Klock A, Jin L, Diem K, Koelle DM, Wald A, Robins H, Corey L. Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature. 2013 May 23;497(7450):494-7.
Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomized, open-label cross-over trials. Lancet. 2012 Feb 18;379(9816):641-7. PMC3420069
Peng T, Zhu J, Phasouk K, Koelle D, Wald A and Corey L. An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of HSV-2 infection. J Virol. 2012 Oct;86(19):10587-96. PMC3457322
Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. PMC2973882
Peng T, Zhu J, Klock A, Phasouk K, Huang ML, Koelle DM, Wald A, Corey L. Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol. 2009 Dec;83(23):12559-68. PMC2786730
Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Magaret A, Wald A, Corey L. Frequent Release of Low Amounts of Herpes Simplex Virus From Neurons: Results of a Mathematical Model. Sci Transl Med. 2009 Nov 1;1(7):7ra16. PMC2818652
Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009 Aug; 15(8):886-92. PMC2723183